# Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

> **NCT04361552** · PHASE3 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Cerebrovascular Accident
- Chronic Obstructive Pulmonary Disease
- Chronic Renal Failure
- Coronary Artery Disease
- Diabetes Mellitus
- Malignant Neoplasm
- SARS Coronavirus 2 Infection

## Interventions

- **OTHER:** Best Practice
- **BIOLOGICAL:** Tocilizumab

## Key facts

- **NCT ID:** NCT04361552
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-04-07
- **Primary completion:** 2020-06-02
- **Final completion:** 2020-06-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study abandoned due to drug billing issues
- **Last updated:** 2020-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361552, "Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04361552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*